mRNA sequencing market to double in value by 2032 due to increased demand and investments.

From GlobeNewswire: 2025-03-19 10:00:00

The mRNA Sequencing Market was valued at USD 3.6 billion in 2023, projected to reach USD 7.19 billion by 2032, growing at a CAGR of 8.0%. Factors like NGS adoption, precision medicine demand, and genomic research investments are driving market expansion, with applications in disease diagnostics, drug discovery, and vaccine development.

mRNA sequencing is gaining popularity for drug development, disease diagnosis, and personalized medicine. Cancer studies, infectious disease research, and diagnostic tests for genetic disorders are driving market growth. Governments and private organizations, like the NIH, are investing in genomics research, with the U.S. providing USD 5.3 billion in 2023.

In 2023, Sequencing by synthesis (SBS) technology dominated the mRNA sequencing market with a 34.3% revenue share. SBS offers high accuracy, scalability, and rapid data production. It is used in gene expression analysis, variant detection, and transcriptome profiling in research institutions, pharmaceutical companies, and diagnostic labs.

Expression profiling analysis accounted for a 30.1% share of the mRNA sequencing market in 2023, crucial for identifying gene expression patterns in diseases like cancer and cardiovascular disease. mRNA sequencing aids in biomarker identification, disease mechanism study, and therapy development, driven by precision medicine’s growth and personalized treatment options.

Academic & research institutions led the mRNA sequencing market in 2023, contributing 52.1% of total revenue. These institutions utilize mRNA sequencing for genomics research, drug discovery, and clinical studies. Funding from organizations like the EU Horizon Europe supports genomics studies, driving demand for mRNA sequencing in understanding complex diseases and developing personalized therapies.

North America dominated the mRNA sequencing market in 2023 with a 42.2% share, driven by high healthcare expenditure, robust research infrastructure, and government support for genomics research. The presence of key market players like Illumina and Thermo Fisher Scientific, along with rising chronic disease prevalence and personalized medicine adoption, boosts market growth. Europe also holds a significant market share due to strict regulatory policies and investments in genomics research. Countries like Germany, the UK, and France lead in taxpayer-funded initiatives and university-pharma partnerships. The Asia-Pacific mRNA Sequencing Market is expected to grow due to healthcare advancements, government funding, and the rise of chronic diseases in countries like China, India, and Japan. Thermo Fisher Scientific gains FDA approval for its Ion Torrent Genexus System. SNS Insider offers in-depth market analysis reports for purchase.



Read more at GlobeNewswire: Global mRNA Sequencing Market to Hit USD 7.19 Billion by